PBS0 Stock Overview An advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Precision BioSciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Precision BioSciences Historical stock prices Current Share Price US$4.40 52 Week High US$17.44 52 Week Low US$3.66 Beta 1.51 1 Month Change -19.27% 3 Month Change -45.00% 1 Year Change -63.33% 3 Year Change -97.34% 5 Year Change -98.77% Change since IPO -99.06%
Recent News & Updates
Precision BioSciences, Inc. Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B Dec 18
Precision BioSciences, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 29
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B Oct 25
Precision BioSciences, Inc Announces Executive Changes Changes Sep 12
Precision BioSciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 30
Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress Jun 06 See more updates
Precision BioSciences, Inc. Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B Dec 18
Precision BioSciences, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 29
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B Oct 25
Precision BioSciences, Inc Announces Executive Changes Changes Sep 12
Precision BioSciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 30
Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress Jun 06 Precision BioSciences, Inc. to Report Q1, 2024 Results on May 13, 2024
Precision BioSciences, Inc., Annual General Meeting, Jun 04, 2024 Apr 28
Precision BioSciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024 Mar 21
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency Mar 06
Precision BioSciences, Inc. has filed a Follow-on Equity Offering. Mar 02 Precision BioSciences, Inc. has filed a Follow-on Equity Offering. Mar 01
Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness Feb 15 Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc. Feb 12
Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure Dec 13
Precision BioSciences, Inc. Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases Dec 05
Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023 Nov 15
Precision BioSciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Nov 02 Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market Oct 26
Precision BioSciences, Inc. Announces Management Changes Sep 09
Second quarter 2023 earnings released: US$0.10 loss per share (vs US$0.46 loss in 2Q 2022) Aug 06
Precision BioSciences, Inc. to Report Q2, 2023 Results on Aug 04, 2023 Aug 03
Precision Biosciences, Inc. Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of in Vivo R&D Day Jul 28
Precision Biosciences, Inc. Announces Oral Presentation of Positive Arcus Gene Editing Data At International Liver Congress 2023 Jun 23
Precision Biosciences, Inc. Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at American Society of Gene & Cell Therapy 26th Annual Meeting May 20
First quarter 2023 earnings released: US$0.23 loss per share (vs US$0.46 loss in 1Q 2022) May 09
No longer forecast to breakeven Mar 11
Full year 2022 earnings released: US$1.27 loss per share (vs US$0.52 loss in FY 2021) Mar 10
No longer forecast to breakeven Mar 09
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, Its Lead Allogeneic Car T Clinical Candidate Jan 07
Precision BioSciences, Inc. Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting Dec 13
Less than half of directors are independent Nov 16
Precision BioSciences, Inc. Announces Raymond Schinazi Resigns from Board and as Chair of Nominating and Corporate Governance Committee and Member of Compensation Committee and Science and Technology Committee Nov 11
Third quarter 2022 earnings released: US$0.22 loss per share (vs US$0.19 loss in 3Q 2021) Nov 09
Precision BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 03
Chief Financial Officer recently bought €61k worth of stock Sep 27
Precision BioSciences, Inc Announces Executive Promotions Sep 03
Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.38 profit in 2Q 2021) Aug 09
Precision BioSciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Aug 02 Precision BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million. Jun 28
Precision BioSciences, Inc.(NasdaqGS:DTIL) dropped from Russell 2000 Dynamic Index
Precision BioSciences, Inc. Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population Jun 10
Precision Biosciences, Inc. Appoints Melinda Brown to its Board of Directors and Chair of the Board’s Audit Committee Jun 01
Precision BioSciences, Inc. Appoints Juli Blanche as Chief People Officer May 24
First quarter 2022 earnings released: US$0.46 loss per share (vs US$0.33 loss in 1Q 2021) May 10
Precision BioSciences, Inc. to Report Q1, 2022 Results on May 09, 2022 May 03
High number of new directors Apr 27
Precision BioSciences, Inc. Announces Shalini Sharp Will Not Seek Re-Election to the Board of Directors Apr 08
Precision BioSciences, Inc., Annual General Meeting, May 10, 2022 Mar 31
Precision BioSciences, Inc., Annual General Meeting, May 10, 2022 Mar 30
Chief Financial Officer recently bought €46k worth of stock Mar 24
Chief Financial Officer recently bought €46k worth of stock Mar 22
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 16
Precision BioSciences, Inc. Reports Clinical Program Updates for Its Allogeneic Car T Pipeline Dec 12
Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.50 loss in 3Q 2020) Nov 11
Second quarter 2021 earnings released: EPS US$0.38 (vs US$0.63 loss in 2Q 2020) Aug 14
Chief Operating Officer David Thomson has left the company Jul 06
Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma Jul 02 Precision BioSciences, Inc.(NasdaqGS:DTIL) dropped from Russell Microcap Value Index Precision Biosciences, Inc. Provides Updates Interim Clinical Results from Its Phase 1/2A Study of PBCAR0191
Precision BioSciences, Inc. Publishes New Study in Nature Communications Using Engineered Arcus Nuclease to Target Mutant Mitochondrial DNA in Vivo Jun 02
Co-Founder recently sold €154k worth of stock May 20
Forecast to breakeven in 2025 May 20
First quarter 2021 earnings released: US$0.33 loss per share (vs US$0.52 loss in 1Q 2020) May 16
Independent Director has left the company May 15
Precision Biosciences, Inc. Announces New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision Biosciences’ Arcus in Vivo Genome Editing May 12
Precision BioSciences Announces Paper Presentation at the Association for Research in Vision and Ophthalmology 2021 Annual Meeting May 04
Full year 2020 earnings released: US$2.10 loss per share (vs US$2.21 loss in FY 2019) Mar 19
Precision BioSciences, Inc. to Report Q4, 2020 Results on Mar 18, 2021 Mar 13
Precision BioSciences, Inc. Announces 3-Year Pre-Clinical Study Results Showing Long-Term Durability and Safety of ARCUS in Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates Feb 20
New 90-day high: €13.00 Feb 10
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma Jan 20
New 90-day high: €11.40 Jan 20
Precision BioSciences Announces Closing of in Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and Company Jan 08 Precision BioSciences, Inc. Announces Shane Barton to Serve as Interim Principal Accounting Officer
Precision BioSciences, Inc. Reports Positive Interim Results from Pbcar0191 Phase 1/2A Trial in Relapsed/Refractory Non-Hodgkin Lymphoma and R/R B-cell Acute Lymphoblastic Leukemia Dec 06 Precision BioSciences, Inc. announced that it expects to receive $34.988367 million in funding from Eli Lilly and Company Shareholder Returns PBS0 DE Biotechs DE Market 7D 0% 5.8% 2.0% 1Y -63.3% -6.1% 9.6%
See full shareholder returns
Return vs Market: PBS0 underperformed the German Market which returned 9.6% over the past year.
Price Volatility Is PBS0's price volatile compared to industry and market? PBS0 volatility PBS0 Average Weekly Movement 9.9% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: PBS0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PBS0's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
Show more Precision BioSciences, Inc. Fundamentals Summary How do Precision BioSciences's earnings and revenue compare to its market cap? PBS0 fundamental statistics Market cap €35.62m Earnings (TTM ) €11.13m Revenue (TTM ) €72.80m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PBS0 income statement (TTM ) Revenue US$75.10m Cost of Revenue US$0 Gross Profit US$75.10m Other Expenses US$63.62m Earnings US$11.48m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 1.50 Gross Margin 100.00% Net Profit Margin 15.28% Debt/Equity Ratio 34.3%
How did PBS0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 01:37 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Precision BioSciences, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Konstantinos Biliouris BMO Capital Markets Equity Research Debjit Chattopadhyay Guggenheim Securities, LLC Debjit Chattopadhyay H.C. Wainwright & Co.
Show 6 more analysts 
